福元医药：1类创新药FY101注射液尚处于I期临床试验阶段

Core Viewpoint - The stock of Fuyuan Pharmaceutical has experienced an abnormal fluctuation, with a cumulative increase of 20% over three consecutive trading days, prompting the company to clarify its operational status and market conditions [1] Company Operations - The company and its subsidiaries are operating normally, with no significant changes in the internal or external environment [1] - There are no undisclosed major issues that require disclosure [1] Market Focus - The market has shown heightened interest in the company's innovative drug business [1] - The company's first-class innovative drug, FY101 injection, has received approval for clinical trial notification and is currently in the Phase I clinical trial stage [1] - There remains significant uncertainty regarding the success of the clinical trial [1]